During the corresponding time, Biorestorative Therapies Inc recorded a revenue increase by 14.6 % year on year, sequentially revenue grew by 46.17 %. While revenue at the Biorestorative Therapies Inc 's corporate clients
Biorestorative Therapies Inc's Comment on Sales, Marketing and Customers
Upon regulatory approval, the company's cell product candidates are intended to be marketed to physicians, health care professionals, hospitals, research institutions, pharmaceutical companies, and the military. The primary users of BRTX-100 for treating discs are expected to be physicians trained in spinal injections, including interventional physiatrists, pain management anesthesiologists, interventional radiologists, and neurosurgeons.
Biorestorative Therapies Inc’s Comment on Sales, Marketing and Customers
Upon regulatory approval, the company's cell product candidates are intended to be marketed to physicians, health care professionals, hospitals, research institutions, pharmaceutical companies, and the military. The primary users of BRTX-100 for treating discs are expected to be physicians trained in spinal injections, including interventional physiatrists, pain management anesthesiologists, interventional radiologists, and neurosurgeons.
Sources:
Biorestorative Therapies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biorestorative Therapies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biorestorative Therapies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
41.43 %